modelOseltamivir
Extends from Pharmacolibrary.Drugs.ATC.J.J05AH02.
Information
| name: | Oseltamivir | |
| ATC code: | J05AH02 | route: | oral |
| compartments: | 1 | |
| dosage: | 75 | mg |
| volume of distribution: | 23.4 | L |
| clearance: | 25.1 | L/h |
| other parameters in model implementation | ||
Oseltamivir is an antiviral medication that inhibits influenza virus neuraminidase, thereby interfering with the release of progeny influenza virus from infected host cells. It is primarily used for the treatment and prophylaxis of influenza A and B. Oseltamivir is approved for clinical use and remains a standard therapy for seasonal influenza.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult subjects (mixed sex, ages 18-65) after single oral dose administration of oseltamivir phosphate.
References
Davies, BE (2010). Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. The Journal of antimicrobial chemotherapy 65 Suppl 2(Suppl 2) ii5–ii10. DOI:10.1093/jac/dkq015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20215135
Rayner, CR, et al., & Jonsson, EN (2008). Population pharmacokinetics of oseltamivir when coadministered with probenecid. Journal of clinical pharmacology 48(8) 935–947. DOI:10.1177/0091270008320317 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18524996
Reddy, MB, et al., & Govorkova, EA (2015). Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. PloS one 10(10) e0138069–None. DOI:10.1371/journal.pone.0138069 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26460484
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)